Nhận Dạng Quốc Tế & Đặc Tính Hóa Học
Công thức hóa học
Dược Lực Học :
Reteplase cleaves the Arg/Val bond in plasminogen to form plasmin. Plasmin in turn degrades the fibrin matrix of the thrombus, thereby exerting its thrombolytic action. This helps eliminate blood clots or arterial blockages that cause myocardial infarction.
Cơ Chế Tác Dụng :
Human tissue plasminogen activator, purified, glycosylated, 355 residues purified from CHO cells. Retavase is considered a "third-generation" thrombolytic agent, genetically engineered to retain and delete certain portions of human tPA. Retavase is a deletion mutein of human tPA formed by deleting various amino acids present in endogenous human tPA. Retavase contains 355 of the 527 amino acids of native human tPA (amino acids 1-3 and 176-527), and retains the activity-related kringle-2 and serine protease domains of human tPA. Three domains are deleted from retavase - kringle-1, finger, and epidermal growth factor (EGF).
Reteplase binds to fibrin rich clots via the fibronectin finger-like domain and the Kringle 2 domain. The protease domain then cleaves the Arg/Val bond in plasminogen to form plasmin. Plasmin in turn degrades the fibrin matrix of the thrombus, thereby exerting its thrombolytic action.
Chỉ Định :
For lysis of acute pulmonary emboli, intracoronary emboli and management of myocardial infarction
Tương Tác Thuốc :
Additive anticoagulant/antiplatelet effects may increase bleed risk. Concomitant therapy should be avoided.
Increased bleeding risk. Monitor for signs of bleeding.
Liều Lượng & Cách Dùng :
Injection, powder, lyophilized, for solution - Intravenous bolus
Tài Liệu Tham Khảo Thêm
National Drug Code Directory